Literature DB >> 2586770

Chronic progressive myelopathy associated with HTLV-I: oligoclonal IgG and anti-HTLV-I IgG antibodies in cerebrospinal fluid and serum.

H Link1, M Cruz, A Gessain, O Gout, G de Thé, S Kam-Hansen.   

Abstract

Among 22 patients with human T-lymphotropic virus type I (HTLV-I)-associated chronic progressive myelopathy, agarose isoelectric focusing (AIF) revealed oligoclonal IgG bands in 21: in 3 in CSF only; in 11 in CSF and to some extent in serum; and in 7, identical patterns in CSF and serum. By immunoblot after AIF of CSF and serum, we observed bands of anti-HTLV-I IgG antibodies in 19 patients: in 5 in CSF only; in 9 in CSF and partly in serum; and in 5, identical in CSF and serum. Oligoclonal anti-HTLV-I IgG antibody bands could only partly be traced to oligoclonal IgG bands. If, prior to AIF, serum and CSF were absorbed with HTLV-I antigen, practically all oligoclonal HTLV-I-specific IgG antibody activity was abolished, while the oligoclonal pattern of total IgG was affected only to a minor extent. Alongside with HTLV-I-specific oligoclonal B cell response, HTLV-I myelopathy is regularly accompanied by production of oligoclonal IgG of unknown antibody specificities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2586770     DOI: 10.1212/wnl.39.12.1566

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Astrocyte-specific expression of human T-cell lymphotropic virus type 1 (HTLV-1) Tax: induction of tumor necrosis factor alpha and susceptibility to lysis by CD8+ HTLV-1-specific cytotoxic T cells.

Authors:  E Méndez; T Kawanishi; K Clemens; H Siomi; S S Soldan; P Calabresi; J Brady; S Jacobson
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Diversity of intrathecal antibody synthesis against HTLV-I and its relation to HTLV-I associated myelopathy.

Authors:  B Kitze; K Usuku; S Izumo; M Nakamura; H Shiraki; S Ijichi; S Yashiki; T Fujiyoshi; S Sonoda; M Osame
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

3.  The role of infections in the pathogenesis and course of multiple sclerosis.

Authors:  Siddharama Pawate; Subramaniam Sriram
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

4.  Multiple sclerosis, tropical spastic paraparesis and HTLV-1 infection in Afro-Caribbean patients in the United Kingdom.

Authors:  P Rudge; A Ali; J K Cruickshank
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

5.  Differential diagnosis of HTLV-I-associated myelopathy and multiple sclerosis in Iranian patients.

Authors:  B Kitze; R W Turner; M Burchhardt; S Poser; G Hunsmann; T Weber
Journal:  Clin Investig       Date:  1992-11

6.  Anti-Borrelia burgdorferi antibody response over the course of Lyme neuroborreliosis.

Authors:  S Baig; T Olsson; K Hansen; H Link
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV.

Authors:  Mark P Burgoon; Barbara N Hammack; Gregory P Owens; Amy L Maybach; M Judith Eikelenboom; Donald H Gilden
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

8.  Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Raya Massoud; Izabela Bialuk; Kory R Johnson; Patrick L Green; Elizabeth M Maloney; Steven Jacobson
Journal:  Retrovirology       Date:  2013-02-13       Impact factor: 4.602

Review 9.  Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP.

Authors:  Yoshimi Enose-Akahata; Ashley Vellucci; Steven Jacobson
Journal:  Front Microbiol       Date:  2017-12-21       Impact factor: 5.640

10.  Standardisation of Western blotting to detect HTLV-1 antibodies synthesised in the central nervous system of HAM/TSP patients.

Authors:  Luiz Claudio Pereira Ribeiro; Cassia Cristina Alves Gonçalves; Carla Maria Sena Andrade Slater; Silvia Maia Farias de Carvalho; Marzia Puccioni-Sohler
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.